We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.
|Original language||English (US)|
|Number of pages||3|
|Journal||Clinical Infectious Diseases|
|State||Published - Jun 1 2008|
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases